other material
confidence high
sentiment neutral
materiality 0.50
BeiGene provides additional 2023 financial data including regional gross margins and product R&D
BeOne Medicines Ltd.
- Total revenue $2.46B; China gross margin 68.0% (2022: 67.1%), ex-China 98.0% (98.3%).
- R&D expense by product: zanubrutinib $158M, tislelizumab $84M, pamiparib $9M, ociperlimab $78M.
- Total R&D expenses $1.78B in 2023 vs $1.64B in 2022; internal R&D $1.13B.
- Key products produced 5.0M vials, sold 3.88M vials; inventory 2.67M vials as of Dec 31, 2023.